Debt-to-equity of Tarsus Pharmaceuticals, Inc. from 30 Jun 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Tarsus Pharmaceuticals, Inc. quarterly Debt-to-equity in % history and change rate from 30 Jun 2021 to 31 Dec 2025.
  • Tarsus Pharmaceuticals, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 55%, a 10% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Tarsus Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 55% +5.1% +10% 31 Dec 2025
Q3 2025 54% +12% +29% 30 Sep 2025
Q2 2025 54% +20% +57% 30 Jun 2025
Q1 2025 54% +26% +90% 31 Mar 2025
Q4 2024 50% +22% +79% 31 Dec 2024
Q3 2024 42% +19% +82% 30 Sep 2024
Q2 2024 34% +14% +66% 30 Jun 2024
Q1 2024 29% +11% +64% 31 Mar 2024
Q4 2023 28% +10% +60% 31 Dec 2023
Q3 2023 23% +8.4% +56% 30 Sep 2023
Q2 2023 21% +8.5% +70% 30 Jun 2023
Q1 2023 17% +7.8% +80% 31 Mar 2023
Q4 2022 17% +11% +176% 31 Dec 2022
Q3 2022 15% +9.4% +174% 30 Sep 2022
Q2 2022 12% +5.6% +84% 30 Jun 2022
Q1 2022 9.7% 31 Mar 2022
Q4 2021 6.3% 31 Dec 2021
Q3 2021 5.4% 30 Sep 2021
Q2 2021 6.6% 30 Jun 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.